Woodcock Outlines Priorities For Next US FDA Commissioner
Along with the pandemic, user fees, IT upgrades and nutrition issues should be at the top of the list, the acting commissioner said.
You may also be interested in...
Califf: More Expedited Approvals Mean US Clearance Only The Beginning Of Learning About Medical Products
The US FDA commissioner said increased use of expedited approval pathways will help spur clinical research system reform.
Sponsors seek clarity about the transition process, which could last a year or longer.
Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.